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This study revisited 18F-fluorodeoxyglucose (18F-FDG) uptake and its relationship to hypoxia in various tumor
models. METHODS: We generated peritoneal carcinomatosis and subcutaneous xenografts of colorectal cancer
HT29, breast cancer MDA-MB-231, and non–small cell lung cancer A549 cell lines in nude mice. The partial oxygen
pressure (pO2) of ascites fluid was measured.
18F-FDG accumulation detected by digital autoradiography was
related to tumor hypoxia visualized by pimonidazole binding and glucose transporter-1 (GLUT-1) in frozen tumor
sections. RESULTS: Ascites pO2 was 0.90 ± 0.53 mm Hg. Single cancer cells and clusters suspended in ascites
fluid as well as submillimeter serosal tumors stained positive for pimonidazole and GLUT-1 and had high 18F-FDG
uptake. In contrast, 18F-FDG uptake was significantly lower in normoxic portion (little pimonidazole binding or
GLUT-1 expression) of larger serosal tumors or subcutaneous xenografts, which was not statistically different from
that in the liver. CONCLUSIONS: Glucose demand (18F-FDG uptake) in severely hypoxic ascites carcinomas and
hypoxic portion of larger tumors is significantly higher than in normoxic cancer cells. Warburg effect originally
obtained from Ehrlich ascites carcinoma may not apply to normoxic cancer cells. Our findings may benefit the
better understanding of 18F-FDG PET in oncology application.
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German biologist Otto Warburg, who hypothesized that even in the
presence of ample oxygen, cancer cells prefer to metabolize glucose by
“aerobic glycolysis” due to mitochondrial dysfunction, the so-called
Warburg effect, found that Ehrlich ascites carcinoma cancer cells had
increased glucose demand [1]. Increased glucose demand is
considered as one of the fundamental features of cancer [2], and it
has been exploited clinically for cancer detection by18F-fluorodeox-
yglucose (18F-FDG, an analog of glucose) positron emission
tomography (PET).
According to the Warburg effect, aerobic glycolysis would confer a
general increase in 18F-FDG uptake throughout all viable cancer cells
of the tumors, spatially unrelated to oxygen status. However, growing
evidence has demonstrated that intratumoral 18F-FDG distribution is
highly heterogeneous and may be hypoxia dependent. Hypoxic
cancer cells have significantly higher radiolabeled FDG uptake in in
vitro [3-6] and in in vivo animal studies [7-9]. While high 18F-FDGuptake is observed in most patients by PET/computed tomography
(CT), 18F-FDG–negative solid malignancies are frequently found
[10,11]. In a clinical study of primary and metastatic non–small cell
lung cancers (NSCLCs), regions of tumor with high levels of
angiogenesis associated with low 18F-FDG uptake were reported
[12]. The 18F-FDG data suggest that hypoxic cancer cells need more
glucose than normoxic cancer cells for biology process.
Warburg used Ehrlich ascites cells because they were almost pure
cultures of cancer cells with which one can work quantitatively as in
chemical analysis, in contrast to solid tumors with a mixture of
Figure 1. Frequency distributions of measured ascites fluid partial
oxygen pressures (pO2 histograms). Three anesthetized live mice
with HT29 ascites carcinomatosis are studied, and a total of 63
measurements are performed.
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condition [21% O2 or partial oxygen pressure (pO2) = 160 mm
Hg].We recently reported that single cancer cells and clusters
of cancer cells suspended in ascites fluid were extensively hypoxic
[13-15], while hypoxia is defined as pO2 less than 10 mm Hg or
1.3% O2. In this study, we directly measured the pO2 of ascites
fluid using OxyLite technology; the presence of hypoxia in ascites
tumors was demonstrated by immunohistochemical visualization of
exogenous and endogenous hypoxia markers, and glucose demand
in ascites tumors was evaluated and measured by 18F-FDG uptake.
Our findings demonstrated that the pO2 in ascites fluid was very
low, and both single cancer cells and cell clusters suspended therein
were severely hypoxic. Moreover, hypoxic cancer cells had higher
18F-FDG uptake than normoxic cancer cells.
Materials and Methods
Cancer Cell Lines and Animals
Three different human cancer cell lines were used in the
experiments: colon cancer HT29, breast cancer MDA-MB-231,
and NSCLC A549. Cells were maintained in McCoy's 5A modified
medium, RPMI 1640, and F-12K medium, respectively. All media
were supplemented with 10% FBS, 1% glutamine, and 1% antibiotic
mixture. Cells were grown at 37°C in a humidified 5% CO2
incubator. Exponentially growing cells were harvested with 0.25%
(wt/vol) trypsin–0.53 mM EDTA solution, washed, and suspended
in phosphate-buffered saline (PBS). The number of viable cells was
counted using a Vi-CELL cell viability analyzer.
All experiments were performed using 6-week-old female athymic
NCr-nu/numice purchased from National Cancer Institute Frederick
Cancer Research Institute (Bethesda, MD). Nude mice were
maintained and used according to institutional guidelines. The
experimental protocols were approved by the Institutional Animal
Care and Use Committees of University of Louisville (Louisville, KY)
and Memorial Sloan-Kettering Cancer Center (New York, NY).
Animals were housed five per cage and kept in the institutional small
animal facility at a constant temperature and humidity. Food pellets
and water were provided ad libitum.
Establishment of Tumor Models in Nude Mice
Cancer cell suspensions (5 × 106 cells in 0.1 ml of PBS) were
injected intraperitoneally and subcutaneously into unanesthetized
mice to generate peritoneal carcinomatosis or subcutaneous xeno-
grafts, respectively. Ascites was generally developed and observed to
be bloody and contained a distribution of free-floating single cancer
cells or cancer cell aggregates (ascites tumors) of sizes up to 1 mm in
diameter 4 to 7 weeks after cancer cell inoculation. At these times,
distributions of serosal tumors ranging from a few hundred
micrometers up to several millimeters in diameter were also present.
Subcutaneous xenografts grew to approximately 1 cm in diameter 3 to
4 weeks after cancer cell inoculation into the hind legs.
Experimental Procedures
Ascites pO2 measurement. Mice were anesthetized by subcutane-
ous injection of ketamine/xylazine (100 mg/10 mg) combination
cocktail (0.2 ml) on the back. A 1-cm incision was carefully made on
the peritoneum wall to explore the peritoneal cavity, and ascites pO2
was measured immediately with an OxyLite probe connected to a
four-channel fiber-optic oxygen-sensing device (OxyLite 4000;Oxford Optronix, Oxford, United Kingdom). The OxyLite probes
were calibrated by the manufacturer before their delivery. A total of
63 measurements were performed using three mice.
Detection of hypoxia in ascites carcinomas and serosal tumors. In
the study, a total of 15 mice, that is 5 mice per cell line, were
examined. The exogenous hypoxia marker pimonidazole hydro-
chloride (1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole hy-
drochloride) (Hypoxyprobe Inc, Burlington, MA) was dissolved in
physiological saline at a concentration of 20 mg/ml, and 0.1 ml of
the solution was injected through the lateral tail vein 1 hour before
animal sacrifice [14]. The blood perfusion marker Hoechst 33342
(Sigma-Aldrich, St Louis, MO) was dissolved in physiological saline
at a concentration of 5 mg/ml and 0.1 ml was injected intravenously
1 minute before animal sacrifice [14]. The cellular proliferation
marker bromodeoxyuridine (Roche Diagnostics, Indianapolis, IN)
first dissolved in DMSO and then in physiological saline (20 mg/
ml) was administered through tail vein injection 1 hour before
animal sacrifice [14]. In all cases, fresh drug solutions were prepared
on the day of injection. Immediately after animal sacrifice, ascites
tumors were harvested, washed with cold PBS to remove red blood
cells, frozen, and embedded in optimal cutting temperature
medium (OCT 4583; Sakura Finetek, Torrance, CA). Serosal
tumors were collected and washed with cold PBS to remove any
attached ascites tumors before freezing, and immediately thereafter,
five contiguous 7-μm-thick tissue sections were cut using a 3050 S
cryostat microtome and adhered to poly-L-lysine–coated glass
microscope slides.
18F-FDG uptake in ascites carcinomas, serosal tumors, and subcutaneous
xenografts. 18F-FDGwas purchased from P.E.T. NET Pharmaceuticals
Inc (Houston, TX). All animals were fasted overnight before experiments,
which were performed without anesthesia. Room air breathing mice were
injected through the tail vein with a mixture of 18F-FDG (7.4MBq) and
pimonidazole (2mg) 1 hour before sacrifice (total injection volume of 0.2
Figure 2. Hypoxia status of ascites carcinoma and peritoneal tumors. (A) A collection of single cancer cell and cancer cell clusters
harvested from ascites after intraperitoneal injection of A549, MDA-MB-231, and HT29 cells, respectively, stained positive for
pimonidazole and GLUT-1, indicating that all ascites carcinomas are hypoxic. The same frozen section is used for both pimonidazole and
GLUT-1 staining (scale bars as indicated). (B) Representative images of A549 and MDA-MB-231 peritoneal tumors that attached to the
serosa. Pimonidazole and GLUT-1–stained positive regions (arrow) suggest hypoxia. Regions with Hoechst 33342 binding (asterisk) have
low pimonidazole and GLUT-1 fluorescence, indicating normoxic cancer cells. Scale bars are indicated. Hematoxylin and eosin stain from
the same or adjacent section is provided for reference.
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minute before sacrifice. A549, HT29, and MDA-MB-231 peritoneal
carcinoma and subcutaneous xenograft-bearing mice were studied.
Visualization of Hypoxia, Perfusion, and Proliferation on
Tumor Sections
Microscopic images of the distributions of pimonidazole, glucose
transporter-1 (GLUT-1), carbonic anhydrase IX (CA9), Hoechst
33342, and bromodeoxyuridine were obtained from the same or
adjacent section as described previously [14,16]. Briefly, slides were
air-dried, fixed in cold acetone (4°C) for 20 minutes, and incubated
with SuperBlock (Pierce Biotechnology, Rockford, IL) at room
temperature for 30 minutes. All antibodies were also applied in
SuperBlock. Sections were then incubated with fluorescein
isothiocyanate–conjugated anti-pimonidazole monoclonal antibody
(Hypoxyprobe Inc), diluted 1:25, for 1 hour at room temperature.
GLUT-1 staining was performed on the same section by incubating
for 1 hour at room temperature with a primary rabbit anti–GLUT-
1 polyclonal antibody (Millipore) diluted 1:50, followed by 1 hour
at room temperature with either Alexa Fluor 568– (for sections co-
stained with pimonidazole) or Alexa Fluor 488–conjugated goat
anti-rabbit antibody (1:100; Molecular Probes, Eugene, OR).
HT29 tumor sections were co-stained for the hypoxia-regulated
protein CA9 by including chimeric anti-CA9 (cG250) antibody (a
gift from Dr Gerd Ritter, Ludwig Institute for Cancer Research,
New York, NY) at a final concentration of 10 μg/ml. Sections were
washed three times in PBS, with each wash lasting 5 minutes. For
CA9 staining, sections were then incubated with Alexa Fluor 568–
conjugated goat anti-human antibody (1:100; Molecular Probes)
and washed again. Due to low expression levels, HCT-8 tumor
sections were not stained for CA9. To control for nonspecific
binding of the pimonidazole antibody, sections were stained from
tumors that had not been exposed to pimonidazole. Controls for
GLUT-1 and CA9 staining consisted of sections where primary
antibody was omitted.
Proliferation marker bromodeoxyuridine staining was performed on
adjacent sections that had been previously imaged for pimonidazole,
GLUT-1, or CA9. Sections were treated with 2 N HCl for 10 minutes
at room temperature followed by 0.1 M Borax for 10 minutes at
room temperature. Sections were then exposed to Alexa Fluor 594–
conjugated anti-bromodeoxyuridine antibody (1:20 dilution; Molecu-
lar Probes) for 1 hour at room temperature and washed.
Images were acquired using a Nikon Eclipse E800 fluorescence
microscope (Nikon America Inc, Melville, NY) equipped with a
motorized stage (Ludi Electronic Products Ltd, Hawthorne, NY).
Pimonidazole and Hoechst 33342 were imaged using green and blue
filters, respectively. CA9 and bromodeoxyuridine were imaged using a
red filter. GLUT-1 was imaged using either a red or a green filter
dependent on secondary antibody.
18F-FDG Digital Autoradiography
Digital autoradiography (DAR) was obtained by placing the tumor
sections in a film cassette against an imaging plate as described
previously [9,13,16,17]. The same plate was used throughout the
experiments; the plate was exposed for ~20 hours and read by a
Cyclone Plus imaging system (PerkinElmer, Inc, Waltham, MA) that
generated digital images with pixel dimensions of 42 × 42 μm. DAR
images were quantified by the OptiQuant software (PerkinElmer
Inc), and tracer uptake was measured as digital light unit per squaremillimeter (DLU/mm2), which was converted to MBq/g, based on
the known section thickness (7 μm) and the system calibration factor,
allowing the results to be expressed as percentage injected dose per
gram tumor tissue (%ID/g).
Statistical Analysis
Ascites fluid pO2 was expressed as median ± SEM, and
18F-FDG
uptake was expressed as mean ± SD. Statistical significance was
examined by two-tailed Student's t-test. A P value less than .05 was
considered as statistically significant difference.
Results
Ascites fluid pO2 measured by OxyLite systems was as low as 0.90 ±
0.53 mm Hg (0.12 ± 0.07% O2, median ± SEM, n = 63
measurements) in three HT29 ascites carcinoma mice (Figure 1).
Ascites pO2 was 0.97 ± 0.68 mm Hg and 1.01 ± 0.55 mm Hg in
A549 and MDA-MB-231 ascites carcinoma models, respectively.
For A549, MDA-MB-231, and HT29 cell lines, all single cancer
cells and ascites tumors (clusters of pure cancer cells) harvested from
ascites fluid were stained positive for both pimonidazole and GLUT-1
(Figure 2A), indicating uniform significant hypoxia. In contrast,
larger serosal tumors contained normoxic (both pimonidazole and
GLUT-1 were negative) and hypoxic (stained positive for pimoni-
dazole and GLUT-1) cancer cells. Representative images from A549
and MDA-MB-231 serosal tumors were presented in Figure 2B.
Similar pattern was observed in HT29 serosal tumors [14].
In A549 peritoneal tumor model, increased glucose demand
detected by 18F-FDG was concurrent with the presence of tumor
hypoxia as shown in Figure 3. In room-air breathing mice, hypoxic
ascites tumors, submillimeter serosal tumors, and hypoxic portions of
larger serosal tumors all had high 18F-FDG uptake (Figure 3A).
However, normoxic portions of larger serosal tumors had significantly
lower 18F-FDG uptake, which was not statistically different from the
activity of liver tissue (Figure 3B). Similar findings were also observed
in HT29 subcutaneous xenograft (Figure 3C). 18F-FDG uptake (%
ID/g) in hypoxic tissue was significantly higher than normoxic
portions of larger A549 serosal tumors (P b .001). Of note, 18F-FDG
uptake in normoxic cancer cells was not statistically different from the
normal liver tissue, stromal tissue, and necrosis (P N .05; Figure 3D).
Results were broadly similar in HT29 and MDA-MB-231 models
(data not shown).
18F-FDG uptake and its relationship to tumor hypoxia, blood
perfusion, and proliferation were summarized in Figure 4. Represen-
tative examples show the relationship between 18F-FDG uptake and
pimonidazole, GLUT-1, CA9, bromodeoxyuridine, and Hoechst
33342 in an HT29 subcutaneous xenograft. There was spatial co-
localization between high levels of 18F-FDG uptake and high
pimonidazole binding and CA9 and GLUT-1 expression. Prolifer-
ating cancer cells are generally located in well-perfused (as detected by
Hoechst 33342) portions of tumors where cancer cells were normoxic
(lack of positive stain of hypoxic markers). Well-perfused and
proliferative cancer cells are generally associated with low 18F-FDG
accumulation. Similar results were obtained from A549 subcutaneous
xenografts that were presented elsewhere [9].
Discussion
The Warburg effect has been considered as a fundamental feature
of cancer for more than 80 years, which states that in the presence
of ample oxygen, cancer cells use glucose by aerobic glycolysis [1].
244 18F-FDG and Hypoxia in Cancer Li et al. Translational Oncology Vol. 7, No. 2, 2014
Figure 3. Comparison of 18F-FDG uptake with tumor hypoxia. (A) 18F-FDG uptake and tumor hypoxia in A549 ascites tumors: ascites
tumors have high 18F-FDG uptake and high pimonidazole binding and GLUT-1 expression. Scale bar is 500 μm. GLUT-1 imaging was
obtained from the adjacent section and all others from the same section. (B) 18F-FDG uptake and tumor hypoxia in A549 serosa tumors:
increased 18F-FDG uptake is coincident with high pimonidazole binding and GLUT-1 expression (hypoxia, as indicated by an arrow).
Regions of the tumor with negative pimonidazole and GLUT-1 stain but high Hoechst 33342 binding (normoxic regions are marked by
asterisks), normal liver, stroma, and necrosis are associatedwith low 18F-FDG uptake. T, tumor tissue; scale bar, 2mm. (C) 18F-FDG uptake
and tumor hypoxia in HT29 subcutaneous xenograft. High 18F-FDG uptake is coincident with high pimonidazole binding as indicated by a
white arrow. Normoxic (red arrow) and necrotic (N) regions are associated with low 18F-FDG uptake; scale bar, 1 mm. Hematoxylin and
eosin stain from the same section is provided for reference. (D) Quantitative 18F-FDG uptake based on a collection of intraperitoneal
tumors. 18F-FDG uptake is significantly higher in hypoxia regions than non-hypoxic (normoxic) tumor tissue, stroma, necrosis, and normal
liver (P b .001 to all). Low 18F-FDG uptake in non-hypoxic tumor tissue is not significantly different from stroma, necrosis, and normal liver.
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detection by 18F-FDG PET. In this study, we have revisited
18F-FDG uptake in cancer. Our data present several challenges to
the Warburg effect.
We have found that pO2 of ascites fluid in mice was generally less
than 1 mm Hg (Figure 1); therefore, it is not surprising that single
cancer cells and clusters of cancer cells were severely hypoxic
(Figure 2) [13,14,16,17], and glucose demand measured by 18F-
FDG uptake was high (Figure 3). Although this agrees with the
increase in glucose demand observed by Warburg, this is unlikely to
be due to mitochondrial dysfunction; it has been proven that the
mitochondrion of cancer cells is functional [18]. It is, however,
probably due to the absence of O2, preventing oxidative phosphor-
ylation and the generation of adenosine triphosphate (ATP) in themitochondria. In addition, hypoxia results in the up-regulation of
glucose transporters and hexokinase proteins [19-22], key facilitators
of glucose uptake and metabolism. Given their hypoxic environment,
ascites cancer cells may use anaerobic glycolysis to generate ATP; it is
unlikely through “aerobic glycolysis” because of the lack of oxygen.
Anaerobic glycolysis is an inefficient biochemical pathway of energy
generation and requires significantly more glucose molecules than
oxidative phosphorylation to produce lesser amounts of ATP, which
induces higher uptake of 18F-FDG in hypoxic cancer cells.
Larger serosal tumors contain relatively well-perfused and
normoxic regions, and the glucose demand measured by18F-FDG
is significantly lower than ascites cancer cells (Figure 3) [16],
suggesting that high glucose demand is not a general feature of
normoxic cancer cells. While normoxic cancer cells had low glucose
Figure 4. Relationship between 18F-FDG uptake and hypoxia, proliferation, and perfusion in HT29 serosal carcinomatosis. Hypoxic
regions, where pimonidazole, GLUT-1, and CA9 are stained positively, have high 18F-FDG uptake (white arrow). Well-perfused regions
where Hoechst 33342 is positive and proliferating cancer cells stained positively for bromodeoxyuridine have low 18F-FDG uptake (red
arrow). All scale bars are 2 mm.
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progress through the division cycle, and this energy demand is
presumably met by high efficacy oxidative phosphorylation for ATP
generation. Of note, normoxic cancer cells have similar levels of 18F-
FDG with liver tissue, intratumoral stromal tissue, as well as necrosis.
Therefore, low 18F-FDG uptake portion of tumor may not indicate
the lack of viable cancer cells.
Proliferation plays an important role in cancer development,
cellular proliferation and hypoxia are generally exclusive, and the
presence of tumor hypoxia is due to the faster proliferation rate of the
cancer cells that are located closer to the functional blood vessels than
the “angiogenesis switch”. Apparently, cell proliferation requires more
energy for the biologic process. Interestingly, proliferating cancer cells
in normoxic cancer zones have lower 18F-FDG uptake compared to
less proliferative cancer cells that are located in hypoxic zones of a
cancerous tumor (Figure 4) [9]. The possible explanation is that
proliferating cancer cells generate ATP from glucose, at least to some
extent, through high efficacy oxidative phosphorylation therefore
requiring less amount of glucose to generate enough energy, in other
words, low 18F-FDG accumulation.
In this study, we have mimicked Warburg's experimental
conditions by generating ascites carcinomas with colon cancer, breast
cancer, and lung cancer cells. Ascites fluid was evident, and ascites
tumors and cancer cells were harvested in all the lines we tested. Our
findings indicated that ascites fluid, cancer cells, and ascites tumors
floating in it were severely hypoxic. Hypoxic ascites carcinomas and
submillimeter serosal tumors had higher glucose demand than less
hypoxic larger serosal tumors generated from the same cancer cell
lines. This pattern is cell line independent, and as we tested lung
cancer cell line A549, breast cancer cell line MDA-MB-231, and
colon cancer cell line HT29, the results were broadly similar.18F-FDG PET-CT scans based on the Warburg effect has been
widely used for cancer detection and therapy response [23-25]. The
success of such utilization is not surprising, because most solid
malignancies have increased 18F-FDG, as hypoxia is a feature of most
solid cancers [26-31]. However, it is also likely that the presence of
associated low 18F-FDG activities of some tumors or tumor regions
[10,11] is probably due to a lack of hypoxia in such tumors or regions of
the tumors. Negative 18F-FDG uptake does not necessarily mean
benign disease.
In both primary lesion and metastases of patients with NSCLC,
Beer et al. [12] demonstrated a mismatched pattern of intratumoral
distribution of 18F-FDG and 18F-galacto-RGD, that is, 18F-FDG
did not accumulate as much in well-perfused regions of the tumor
identified by increased 18F-galacto-RGD, which binds to the αvβ3
expressed by endothelial cells. Therefore, in patients, well-perfused
cancer tissue is associated with low 18F-FDG uptake or low glucose
demand. Accordingly, assumptions in 18F-FDG PET interpretations
for cancer management should be reconsidered because low 18F-FDG
uptakes in tumor following treatment may not necessarily mean the
absence of viable cancer cells.
18F-FDG preferentially accumulates in hypoxic cancer cells, and
3′-deoxy-3′-18F-fluorothymidine accumulates mostly in proliferative
cancer cells, which are usually not hypoxic [7,9]. We have recently
proposed that the combination of 18F-FDG and 3′-deoxy-3′-18F-
fluorothymidine with single PET imaging would give a more accurate
representation of viable tumor tissue volume than a PET image
obtained with either tracer alone [32].
We emphasize here that the DAR signal of 18F-FDG is directly
contributed by positrons and not gamma photons. In a pilot study,
we have inserted a piece of blanket poly-L-lysine–coated glass
microscope between the plate and the tumor section slide, and
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positron in 18F-FDG autoradiography. We are confident that the
spatial correlation between 18F-FDG autoradiography and immuno-
histochemical staining photos presented in this article is true.
Conclusion
In the mouse model of ascites carcinoma, ascites and floating ascites
carcinomas are severely hypoxic, contradicting the assumed ample
oxygen condition of the Ehrlich ascites carcinoma model in which the
“Warburg effect” was derived from. Glucose utilization measured by
18F-FDG uptake increases in hypoxic but not normoxic cancer cells,
posing a challenge for the conventional Warburg effect. The
knowledge enriches the better understanding of 18F-FDG in
oncology application.
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